BHVN - NYSE

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%

HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.14B

EPS-6.8600

P/E Ratio-1.58

Earnings Date08/10/2026

451.45M

Assets

-27%

3Y-32.0%

5Y+305.0%

10Y+207.0%

399.38M

Total Liabilities

108%

3Y+225.0%

5Y+1050.0%

10Y+2577.0%

52.07M

Total Equity

-88%

3Y-90.0%

5Y-32.0%

10Y-61.0%

Biohaven Ltd. Funding & Solvency Profile

BHVN · NYSE

Current Assets

Cash & Cash Equivalents229.96M

Net Receivables0.00

Inventory0.00

Other Current Assets49.19M

Total Current Assets368 M

Non-Current Assets

Property, Plant & Equipment15.96M

Goodwill & Intangible Assets19.79M

Long-Term Investments0.00

Other Non-Current Assets47.36M

Total Non-Current Assets63 M

Total Assets

451.45M

Financial Health Analysis

Current Ratio

3.18x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

7.67x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

252 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

82% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Biohaven Ltd. Balance Sheet

BHVN • NYSE

Biohaven Ltd. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	230M	99.1M	248.4M	204.9M	76.1M	82.5M	316.7M	264.2M	131.5M
Short-Term Investments	89.2M	386.9M	133.4M	260.5M	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	319.1M	486M	381.8M	465.3M	76.1M	82.5M	316.7M	264.2M	131.5M
Net Receivables	0.0	2.6M	13.3M	46.1M	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	2.6M	13.3M	46.1M	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	49.4M	35.2M	20.9M	6.7M	7.2M	0.0	0.0	0.0
Other Current Assets	49.2M	508K	12.1M	54.5M	12M	10K	11.6M	8.1M	5.2M
Total Current Assets	368.3M	538.5M	442.4M	587M	94.8M	89.8M	328.3M	272.3M	136.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	16M	53.7M	48.6M	52.4M	17.7M	13.6M	8.2M	6.2M	2.3M
Goodwill	1.4M	1.4M	1.4M	1.4M	1.4M	0.0	0.0	0.0	0.0
Intangible Assets	18.4M	18.4M	18.4M	18.4M	18.9M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	19.8M	19.8M	19.8M	19.8M	20.3M	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	6M	7.2M	0.0	0.0	0.0
Other Non-Current Assets	47.4M	3.1M	2.4M	2.6M	3.2M	1M	7.8M	11.4M	7.9M
Total Non-Current Assets	83.1M	76.6M	70.8M	74.8M	47.2M	21.7M	16M	17.7M	10.2M
Total Assets	451.4M	615.1M	513.2M	661.8M	142.1M	111.5M	344.3M	290M	146.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	11.6M	18M	15.6M	45.9M	4.8M	2.8M	14.1M	10.8M	4.7M
Accounts Payable	11.6M	18M	15.6M	10.7M	4.8M	2.8M	14.1M	10.8M	4.7M
Other Payables	0.0	0.0	0.0	35.2M	0.0	0.0	0.0	-10.8M	-4.7M
Accrued Expenses	0.0	47.7M	36.5M	26.5M	36.7M	18.9M	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3.8M	3.3M	3M	439K	675K	0.0	0.0	0.0
Other Current Liabilities	104.3M	84.7M	0.0	14.6M	0.0	7.6M	52.1M	8.8M	4.7M
Total Current Liabilities	115.9M	154.2M	55.4M	90M	41.9M	29.9M	66.2M	19.5M	9.4M
NON-CURRENT LIABILITIES
Long Term Debt	278.9M	0.0	0.0	0.0	0.0	0.0	0.0	117.5M	0.0
Other Non-Current Liabilities	4.6M	4.7M	2.2M	2.4M	2.6M	1.9M	285.5M	2M	5.5M
Total Non-Current Liabilities	283.4M	37.4M	29.8M	33M	5.4M	4.8M	285.5M	119.6M	5.5M
Capital Lease Obligations	0.0	36.6M	30.9M	33.6M	3.2M	3.6M	0.0	0.0	0.0
Total Liabilities	399.4M	191.7M	85.2M	123M	47.4M	34.7M	351.7M	139.1M	14.9M
SHAREHOLDERS' EQUITY
Common Stock	1.9B	1.7B	887.5M	615.7M	34.7M	16.8M	881.4M	554.4M	311.1M
Additional Paid-In Capital	0.0	112.4M	39.8M	13.9M	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-2.1B	-1.3B	-499.3M	-91.1M	0.0	0.0	-972.4M	-443.6M	-202.6M
Accumulated Other Comprehensive Income/Loss	8.3M	79K	-65K	284K	0.0	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	194M	0.0	0.0	0.0	0.0	0.0	83.5M	40.1M	23.6M
Total Stockholders' Equity	52.1M	423.4M	428M	538.8M	34.7M	16.8M	-7.4M	150.9M	132M
Total Equity	52.1M	423.4M	428M	538.8M	94.7M	76.8M	-7.4M	150.9M	132M
Minority Interest	0.0	0.0	0.0	0.0	60M	60M	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	451.4M	615.1M	513.2M	661.8M	142.1M	111.5M	344.3M	290M	146.9M
Total Investments	89.2M	386.9M	133.4M	260.5M	6M	7.2M	0.0	0.0	0.0
Total Debt	278.9M	36.6M	30.9M	33.6M	3.2M	3.6M	0.0	117.5M	0.0
Net Debt	48.9M	-62.6M	-217.5M	-171.3M	-72.8M	-78.9M	-316.7M	-146.7M	-131.5M
Shares Outstanding	105,790,997	105,790,997	105,790,997	105,790,997	105,790,997	105,790,997	105,790,997	105,790,997	105,790,997

SEC Filings

BHVN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	April 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 13, 2026	April 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 06, 2026	2026	View Filing

Showing 1 to 10 of 69 filings

Related Guides

Blog Categories

Continue your BHVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.